Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A human milk oligosaccharide (HMO) mix is a combination of complex carbohydrates that are naturally found in human breast milk. [18] There are over 200 distinct types of HMOs. [2, 6, 17] These compounds are not easily digested by humans and travel to the colon, where they act as prebiotics. [6] Their primary mechanism involves selectively promoting the growth of beneficial gut bacteria, such as Bifidobacterium, which can be depleted in individuals with certain conditions. [4, 9] By modulating the gut microbiota, HMO mixes are believed to strengthen the gut barrier, reduce inflammation, and support immune function. [4, 23] As seen in a clinical trial sponsored by DSM, this has led to their investigation as a potential therapeutic for conditions like Irritable Bowel Syndrome (IBS). [4] DSM markets its HMO products under the brand name GlyCare. [11] A 2019 study by Palsson et al. investigated a mix of 2'-fucosyllactose and lacto-N-neotetraose for IBS. [13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human milk oligosaccharide mix.